Q BioMed Adds to Leadership Team With Global Head of Regulatory Affairs

NEW YORK, March 31, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company,  announced today the appointment of Geoff Fatzinger as the Global Head of Regulatory Affairs. Geoff will be responsible for providing strategic regulatory oversight to Q BioMed for product development and commercialization. Specifically, he will be focused on developing the global regulatory approval strategy for the commercialization of Q BioMed's lead product, the FDA approved, non-opioid Strontium89  (Strontium Chloride Sr-89 Injection, USP). He will also contribute strategic regulatory insight and guidance to the Company's portfolio of earlier stage assets.

Geoff brings over 20 years of regulatory expertise, having been directly involved in all phases of product development with a demonstrated record of regulatory and business accomplishments covering the United States, Europe, Middle East and Asia Pacific with in-depth experience in Japan, China, and Korea. His specialties include global product regulatory strategy development; market assessments; agency interactions; Health Economics Outcomes Research (HEOR) and Regulatory Economics; extensive global experience in drug and device development; clinical trials, and approvals, including such areas as: biosimilar development and approval; nanotechnology, stem cell and gene therapy products, medical devices; in-licensing and divestitures; and regulatory due diligence.

"We are very happy to have Geoff join the team at Q BioMed. His deep global regulatory expertise and strategic leadership is critical as we reach some important milestones, including our effort to globally commercialize Strontium89," said Q BioMed CEO Denis Corin. "We look forward to his contributions and are pleased with the strength we've continued to build in our leadership team."

"Q BioMed is taking on projects which are providing medical benefit to those with byproducts of illnesses which often go overlooked or minimised. Medicine is not about the 'flavour of the month'," said Geoff Fatzinger. "I look forward to helping achieve these goals and bringing medicines to those who need it."

Q BioMed received FDA approval to manufacture and distribute Strontium89 in November, 2019. The Company completed its initial commercial production run and shipment in February and has begun distribution in the US, with distribution to EU and rest of the world expected later in the year.

About Q BioMed Inc.

Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Please visit http://www.QBioMed.com and sign up for regular updates.

Forward-Looking Statements:

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

Q BioMed Media Contact:
Denis Corin
CEO

Investor Relations:
Keith Pinder 
+1(404)995-6671
[email protected]

SOURCE Q BioMed Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED